CLAIM AMENDMENTS

1. (currently amended) A transgenic mouse whose genome comprises a transgene comprising mouse SM22α promoter operably linked to a cDNA encoding a ~~mouse~~ calreticulin (CRT) peptide~~, said peptide having at least 80% homology to~~ as set forth in SEQ ID No. 23,

wherein expression of calreticulin from the mouse SM22α promoter in the vascular smooth muscle cells of the transgenic mouse results in hemangioma formation.

2. cancelled.

3. (currently amended) A transgene comprising mouse SM22α promoter operably linked to a cDNA encoding a ~~mouse~~ calreticulin peptide~~, said peptide having at least 80% homology to~~ as set forth in SEQ ID No. 23.

4. (currently amended) A method for producing a transgenic mouse that exhibits hemangioma comprising:

introducing into a fertilized mouse egg a transgene comprising mouse SM22α promoter operably linked to a cDNA encoding a mouse calreticulin (CRT) peptide, said peptide having at least 80% homology to SEQ ID No. 23;

transplanting the injected egg in a foster parent female mouse; and

selecting a mouse derived from an injected egg whose genome comprises mouse SM22α promoter operably linked to a cDNA encoding a ~~mouse~~ calreticulin peptide~~, said peptide having at least 80% homology to~~ as set forth in SEQ ID No. 23,

wherein expression of calreticulin from the mouse SM22α promoter in the vascular smooth muscle cells of the transgenic mouse results in hemangioma formation.

5. cancelled.

6. (withdrawn) A method for screening compounds that inhibit vascular tumor formation in a transgenic mouse comprising

providing a transgenic mouse whose genome comprises a transgene comprising a transcriptional control region operably linked to a cDNA encoding calreticulin (CRT);

allowing CRT to be expressed in said transgenic mouse

administering a compound to said mouse; and

determining whether said compound reduces hemangioma formation.

7. (withdrawn) A compound isolated according to the method of claim 6.

8. (withdrawn) A method of testing the therapeutic activity of a pharmacological agent on Kaposiform hemangioenothelioma comprising administering an effective amount of said pharmacological agent to the mouse of claim 1 and evaluating said agent's effect on hemangioma formation of said mouse.

9. (withdrawn) A compound isolated according to the method of claim 8.

10. (withdrawn) A method of inhibiting hemangioma formation comprising administering an effective amount of a matrix metalloproteinase inhibitor to a patient in need of such treatment.

11. (withdrawn) A method of inhibiting hemangioma comprising administering to an individual in need of such treatment an effective amount of virally-administered small interference RNA (siRNA) corresponding to a portion of CRT mRNA, wherein expression of the siRNA decreases the level of CRT.

12. cancelled.

13. cancelled.

14. (previously presented) The transgenic mouse according to claim 1 wherein the mouse SM22α promoter is a DNA sequence corresponding to nucleotides 1 to 1343 of SEQ ID No. 1.

15. cancelled.

16. cancelled.

17. (previously presented) The method according to claim 4 wherein the mouse SM22α promoter is nucleotides 1 to 1343 of SEQ ID No. 1.

18. (previously presented) The transgene according to claim 3 wherein the transgene is nucleotides 1 to 2655 of SEQ ID No. 1.

19. (previously presented) The transgene according to claim 3 wherein the transgene is nucleotides 1 to 2691 of SEQ ID No. 12.